Unimet Tablet 50/850 mg
Sitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Korea Union Pharmaceutical Co., Ltd.
MFDS item code 201506699 · Approved 2015.09.23
This product's status changed to Expired on 2025.09.23. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used in conjunction with dietary and exercise therapy to improve blood sugar control in patients with Type 2 diabetes. It effectively manages blood sugar levels by combining sitagliptin and metformin, helping to stabilize blood sugar levels. This contributes to the prevention of complications related to diabetes and overall health improvement. Therefore, it is used to enhance blood sugar control in patients with Type 2 diabetes.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this medicine is determined based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous experience with antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom sitagliptin monotherapy does not provide adequate glycemic control, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients in whom this medicine must not be administered). 2. Patients receiving metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's existing metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this medicine may start at their existing doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should take into account the patient's blood glucose level and existing dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When this medicine is administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia caused by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral glucose-lowering medicines to this medicine. Any change in treatment for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine, because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients in whom this medicine must not be administered).
This medication contains sitagliptin and metformin, which are used for diabetes treatment. First, when taking this medication, severe allergic reactions may occur, so if symptoms such as hives or difficulty breathing develop, discontinue use immediately and consult a physician. Additionally, this medication may cause severe inflammation of the pancreas known as pancreatitis, so if abdominal pain, vomiting, or severe abdominal discomfort occurs, seek medical attention promptly. The metformin component can cause a rare but fatal metabolic abnormality known as lactic acidosis, so if symptoms such as shortness of breath, muscle pain, extreme fatigue, or abdominal pain occur, inform a healthcare professional immediately. This medication should not be administered to patients with severely impaired kidney function, severe infections or dehydration, heart failure, or acute myocardial infarction. Particularly, if undergoing tests that use contrast agents, this medication should be discontinued for a certain period before and after the test, and should only be resumed once normal kidney function is confirmed. Women who are pregnant or may become pregnant, as well as nursing mothers, should not use this medication, and its safety and efficacy have not been established in children under 18 years of age. During treatment, the risk of hypoglycemia may increase due to irregular meals, excessive exercise, or interactions with other medications, so caution is advised. While taking this medication, it is advisable to have regular kidney function and blood checks, as well as periodic monitoring of vitamin B12 levels. Furthermore, alcohol consumption can increase the risk of lactic acidosis, so it should be avoided during treatment. In cases of surgery, discontinue this medication 48 hours prior and only resume once normal kidney function has been confirmed after recovery. Side effects such as diarrhea, nausea, vomiting, headache, upper respiratory infections may occur while taking this medication, and if severe joint pain, skin rashes, or blistering diseases develop, inform a physician immediately. Finally, when using this medication alongside insulin or other blood sugar-lowering agents such as sulfonylureas, the risk of hypoglycemia may increase, so if symptoms occur, immediately consume sugar and consult with a physician.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container that is well-ventilated, at room temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the efficacy of the medication for a longer period.
Pink oval film-coated tablet
In-house packaging unit
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Korea Union Pharmaceutical Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Jongkun Dang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
Jong Kun Dang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
JongKeunDang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Yuyu Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.